DelveInsight’s “HER2-Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the HER2-Negative Breast Cancer, historical and forecasted epidemiology as well as the HER2-Negative Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
HER2 Negative Breast Cancer Key Highlights
-
Key Companies working in the her2 Negative Breast Cancer market include BeiGene
Eisai Pharmaceuticals, and many others
-
Key Therapies included in the her2 Negative Breast Cancer market include Doxorubicin
Cyclophosphamide and many others
HER2 Negative Breast Cancer Overview
HER2-negative negative breast cancer means that the cancerous cells do not contain high levels of the protein HER2. There are many treatment options available for this type of breast cancer, but the outlook can vary. “HER2” stands for human epidermal growth factor receptor 2. HER2 proteins are receptors that sit on the surface of breast cells. They usually help control the growth and repair of healthy breast tissue.However, when the HER2 gene becomes faulty and starts making too many copies of itself, it overproduces HER2 proteins on the surface of breast cells. This can result in HER2-positive cancer.
HER 2 Negative Breast Cancer Epidemiology Insights
-
According to the American Cancer Society and National Cancer Institute, the current estimates for breast cancer for the year 2020 include: Incidence of female breast cancer estimated to be 276,480 new cases.
-
About 48,530 new cases of carcinoma in situ (CIS) will be diagnosed (CIS is non-invasive and is the earliest form of breast cancer).
-
About 42,170 women will die from breast cancer.2,3
Click here to learn more about the her2 Negative Breast Cancer Market Landscape
The Report Covers the her2 Negative Breast Cancer Epidemiology Segmented by:
-
her2 Negative Breast Cancer prevalent cases
-
her2 Negative Breast Cancer incident cases
-
her2 Negative Breast Cancer treatment cases
-
her2 Negative Breast Cancer diagnosed cases
HER2 Negative Breast Cancer Market Outlook
The HER2-Negative Breast Cancer market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted HER2-Negative Breast Cancer market trends by analyzing the impact of current HER2-Negative Breast Cancer therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of HER2-Negative Breast Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated HER2-Negative Breast Cancer market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the HER2-Negative Breast Cancer market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Companies Working in the her2 Negative Breast Cancer Market
-
BeiGene
-
Eisai Pharmaceuticals
And many others
HER 2 Negative Breast Cancer Therapies Covered and Analyzed in the Report
-
Doxorubicin
-
Cyclophosphamide
And many others
Learn more about the Key Companies and Emerging Therapies in the her2 Negative Breast Cancer Market
Table of Contents
-
Key Insights
-
her2 Negative Breast Cancer Introduction
-
Executive Summary of her2 Negative Breast Cancer
-
Disease Background and Overview
-
Epidemiology and patient population
-
her2 Negative Breast Cancer Emerging Therapies
-
her2 Negative Breast Cancer Market Outlook
-
Market Access and Reimbursement of Therapies
-
Market Drivers
-
Market Barriers
-
Appendix
-
Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Learn about the detailed offerings of the report @ her2 Negative Breast Cancer Market Outlook
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services